You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 13, 2024

Delcath Systems Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for DELCATH SYSTEMS INC, and what generic alternatives to DELCATH SYSTEMS INC drugs are available?

DELCATH SYSTEMS INC has one approved drug.

There are ten US patents protecting DELCATH SYSTEMS INC drugs.

There are nineteen patent family members on DELCATH SYSTEMS INC drugs in nine countries and five supplementary protection certificates in four countries.

Summary for Delcath Systems Inc
International Patents:19
US Patents:10
Tradenames:1
Ingredients:1
NDAs:1

Drugs and US Patents for Delcath Systems Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Delcath Systems Inc HEPZATO melphalan hydrochloride POWDER;INTRA-ARTERIAL 201848-001 Aug 14, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up
Delcath Systems Inc HEPZATO melphalan hydrochloride POWDER;INTRA-ARTERIAL 201848-001 Aug 14, 2023 RX Yes Yes ⤷  Sign Up ⤷  Sign Up
Delcath Systems Inc HEPZATO melphalan hydrochloride POWDER;INTRA-ARTERIAL 201848-001 Aug 14, 2023 RX Yes Yes 11,833,286 ⤷  Sign Up Y ⤷  Sign Up
Delcath Systems Inc HEPZATO melphalan hydrochloride POWDER;INTRA-ARTERIAL 201848-001 Aug 14, 2023 RX Yes Yes 10,195,334 ⤷  Sign Up Y ⤷  Sign Up
Delcath Systems Inc HEPZATO melphalan hydrochloride POWDER;INTRA-ARTERIAL 201848-001 Aug 14, 2023 RX Yes Yes 11,083,831 ⤷  Sign Up Y ⤷  Sign Up
Delcath Systems Inc HEPZATO melphalan hydrochloride POWDER;INTRA-ARTERIAL 201848-001 Aug 14, 2023 RX Yes Yes 10,369,264 ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for Delcath Systems Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2701720 122023000007 Germany ⤷  Sign Up PRODUCT NAME: MELPHALANFLUFENAMID HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 20220817
2701720 CR 2022 00054 Denmark ⤷  Sign Up PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818
2701720 23C1000 France ⤷  Sign Up PRODUCT NAME: MELPHALAN FLUFENAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/22/1669 20220818
2701720 3/2023 Austria ⤷  Sign Up PRODUCT NAME: MELPHALANFLUFENAMID-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 (MITTEILUNG) 20220818
2701720 CA 2022 00054 Denmark ⤷  Sign Up PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.